10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________  to____________

Commission file number 0-7473

Amexdrug Corporation

(Exact name of registrant as specified in its charter)

NEVADA	95-2251025
(State or other jurisdiction of  incorporation or organization)	(I.R.S. Employer identification No.)

7251 Condor Street

Commerce, California 90040

(Address of principal executive offices)  (Zip code)

Registrant's telephone number: (323) 725-3100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [  ]  No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [  ]	Accelerated filer [  ]
Non-accelerated filer   [  ] (Do not check if a smaller reporting company)	Smaller reporting company [ X ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [ X ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of May 14, 2013, there were 169,409,620 shares of the issuer’s common stock issued and outstanding, including 300,440 shares held as treasury shares.

AMEXDRUG CORPORATION

FORM 10-Q

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

	Page
Item 1.   Financial Statements (Unaudited)	3
Consolidated Balance Sheets — As of March 31, 2013 (Unaudited) and December 31, 2012 (Audited)	4
Consolidated Statements of Operations for the Three Months Ended March 31, 2013 and 2012 (Unaudited)	5
Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012 (Unaudited)	6
Notes to Consolidated Financial Statements (Unaudited)	7
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.   Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.   Controls and Procedures	14
PART II – OTHER INFORMATION
Item 1.   Legal Proceedings	14
Item 1A. Risk Factors	14
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.   Defaults Upon Senior Securities	14
Item 4.   Mine Safety Disclosures	14
Item 5.   Other Information	14
Item 6.   Exhibits	15

2

PART I - FINANCIAL INFORMATION

Item 1.   Financial Statements.

The consolidated balance sheets of Amexdrug Corporation, a Nevada corporation, and subsidiaries as of March 31, 2013 (unaudited) and December 31, 2012 (audited), the related unaudited consolidated statements of operations for the three month periods ended March 31, 2013 and March 31, 2012, the related unaudited consolidated statements of cash flows for the three month periods ended March 31, 2013 and March 31, 2012 and the notes to the unaudited consolidated financial statements follow.  The consolidated financial statements have been prepared by Amexdrug’s management, and are condensed; therefore they do not include all information and notes to the financial statements necessary for a complete presentation of the financial position, results of operations and cash flows, in conformity with accounting principles generally accepted in the United States of America, and should be read in conjunction with the annual consolidated financial statements included in Amexdrug’s annual report on Form 10-K for the year ended December 31, 2012.

The accompanying consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the results of operations and financial position of Amexdrug Corporation consolidated with BioRx Pharmaceuticals, Inc., Allied Med, Inc. and Dermagen, Inc., its wholly owned subsidiaries, and all such adjustments are of a normal recurring nature.  The names “Amexdrug”, “we”, “our” and “us” used in this report refer to Amexdrug Corporation.

Operating results for the quarter ended March 31, 2013, are not necessarily indicative of the results that can be expected for the year ending December 31, 2013.

3

AMEXDRUG CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2013			December 31, 2012
	(Unaudited)
Assets
Current Assets
Cash and cash equivalents	$	125,972		$	415,962
Investment		5,348			5,991
Accounts receivable, net of allowance of $7,833 and $7,833, respectively		640,419			558,569
Prepaid expenses		-			77,605
Inventory		832,633			800,936
Other asset		11,425			11,002
Total Current Assets		1,615,797			1,870,065
Property and Equipment, at cost
Office and computer equipment		700,736			698,339
Leasehold improvements		15,700			15,700
		716,436			714,039
Less accumulated depreciation		(242,577	)		(224,935	)
Net Property and Equipment		473,859			489,104
Other Assets
Other deposits		29,862			29,862
Intangibles
Customer base, net of accumulated amortization of $18,259		-			-
Trademark, net of accumulated amortization of $42 and $1,002, respectively		606			648
Goodwill		17,765			17,765
Total Other Assets		48,233			48,275
Total Assets	$	2,137,889		$	2,407,444
Liabilities and Shareholders' Equity
Current Liabilities:
Accounts payable	$	387,094		$	697,339
Accrued liabilities		8,284			8,780
Deferred operating lease liability		13,192			14,590
Deferred tax liability		55,500			57,300
Corporate tax payable		1,915			-
Notes payable related parties		108,023			108,023
Business lines and short term promissory note		589,405			697,842
Promissory note, current portion		58,370			58,370
Total Current Liabilities		1,221,783			1,642,244
Long Term Liabilities
Promissory note		315,347			335,550
Total Long Term Liabilities		315,347			335,550
Total Liabilities		1,537,130			1,977,794
Shareholders' Equity
Common stock, $.001 par value; 1,000,000,000 authorized common shares 169,409,620 shares issued and outstanding		169,410			169,410
Additional paid in capital		(77,594	)		(77,594	)
Treasury stock		(16,169	)		(14,933	)
Retained earnings		525,112			352,767
Total Shareholders' Equity		600,759			429,650
Total Liabilities and Shareholders' Equity	$	2,137,889		$	2,407,444

The accompanying notes are an integral part of these consolidated financial statements

4

AMEXDRUG CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended
	March 31, 2013			March 31,  2012
Sales	$	2,360,911		$	2,180,990
Cost of Goods Sold		1,842,165			1,820,350
Gross Profit		518,746			360,640
Operating Expenses
Selling, general and administrative expense		243,208			188,842
Total Operating Expenses		243,208			188,842
Income  before depreciation expense		275,538			171,798
Depreciation and amortization expense		17,683			2,472
Income before Other Income/(Expenses)		257,855			169,326
Other Income/(Expenses)
Interest and other income		1			2
Unrealized gain/(loss)		618			1,415
Interest expense		(8,409	)		(5,372	)
Total Other Income/(Expenses)		(7,790	)		(3,955	)
Income before Provision for Income Taxes		250,065			165,371
Income tax expense		(77,720	)		(61,286	)
Net Income	$	172,345		$	104,085
BASIC AND DILUTED INCOME PER SHARE	$	0.00		$	0.00
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC AND DILUTED		169,409,620			169,409,620

The accompanying notes are an intergral part of these consolidated financial statements

5

AMEXDRUG CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2013			March 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	172,345		$	104,085
Adjustment to reconcile net income to net cash used in operating activities
Depreciation and amortization		17,683			2,472
Unrealized (gain)/loss on investment		(618	)		(1,415	)
Allowance for doubtful accounts		0			-
Adjustment to retained earnings		-			-
Change in Assets and Liabilities
(Increase) Decrease in:
Accounts receivable		(81,850	)		110,934
Inventory		(31,697	)		(215,612	)
Prepaid expenses		77,605			45,513
Deferred tax asset		-			8,009
Other assets		(422	)		(45,513	)
Increase (Decrease) in:
Accounts payable and accrued liabilities		(310,744	)		(69,796	)
Deferred operating lease liability		(1,397	)		1,352
Deferred tax liability		(1,800	)		-
Corporate income tax payable		1,915			53,277
NET CASH USED IN OPERATING ACTIVITIES		(158,980	)		(6,694	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments		1,261			-
Proceeds from the sale of investment		-			(2,028	)
Purchase of fixed assets		(2,397	)		-
NET CASH USED BY INVESTING ACTIVITIES		(1,136	)		(2,028	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on related party loans		-			(1,671	)
Payments on related party loans		-			-
Purchase of treasury stock		(1,235	)		(947	)
Proceeds from pronissory note		-			-
Payments on promissory note		(20,202	)
Proceeds from credit line		(108,437	)		(450,425	)
NET CASH USED BY FINANCING ACTIVITIES		(129,874	)		(453,043	)
NET DECREASE IN CASH		(289,990	)		(461,765	)
CASH, BEGINNING OF PERIOD		415,962			589,472
CASH, END OF PERIOD	$	125,972		$	127,707
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	$	6,253		$	3,212
Income taxes	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements

6

AMEXDRUG CORPORATION AND SUBSIDIARIES

NOTES TO FINANCIAL STATEMENTS-UNAUDITED

MARCH 31, 2013

1.     BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.  For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2012.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of AmexDrug Corporation is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Income per Share Calculations

Income per Share dictates the calculation of basic earnings per share and diluted earnings per share. Basic earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted income per share is the same as the basic income per share for the three months ended March 31, 2013, because there are no outstanding dilutive instruments.

3.     CAPITAL STOCK

During the three months ended March 31, 2013, the Company issued no shares of common stock.

4.     INCOME TAXES

The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2009.

The Company accounts for uncertainty in tax positions by recognition in the financial statements.

The Company's policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

5.     BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

7

AMEXDRUG CORPORATION AND SUBSIDIARIES

NOTES TO FINANCIAL STATEMENTS-UNAUDITED

MARCH 31, 2013

5.     BUSINESS SEGMENT INFORMATION (Continued)

The following tables describe information regarding the operations and assets of these reportable business segments:

			Health and
			Beauty
	Distributions		Products		Total
For the period ended March 31, 2013
Sales to external customers	$	1,718,431	$	642,480	$	2,360,911
Depreciation and amortization		1,309		16,374		17,683
Segment income (loss) before taxes		93,357		156,708		250,065
Segment assets		631,667		1,506,222		2,137,889
For the period ended March 31, 2012
Sales to external customers	$	1,788,075	$	392,915	$	2,180,990
Depreciation and amortization		933		1,539		2,472
Segment income (loss) before taxes		64,258		101,113		165,371
Segment assets		679,594		554,783		1,234,377

6.      SUBSEQUENT EVENT

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has determined there are no subsequent events to be reported.

7.      COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company moved to a new facility and signed a new operating lease for three years as of March 1, 2011. The monthly lease payments per month are $7,600. There are future minimum rental payments required under the operating leases for the facility.  The lease of the facility expires in 2014.

Legal Contingency

On March 19, 2013, the Company received notice of a claim filed by a vendor requesting an additional payment of $38,264 for  a piece of equipment that was purchased by the Company. The Company has a counter claim filed against the vendor for misrepresentation about the performance of the piece of equipment purchased. The Company has retained counsel to aggressively defend the matter.

8

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

Amexdrug Corporation is located at 7251 Condor Street, Commerce, California 90040.  Its phone number is (323) 725-3100.  Its fax number is (323) 725-3133. Its website is www.amexdrug.com.  Shares of Amexdrug common stock are traded on the OTC Bulletin Board under the symbol AXRX.OB.  The President of Amexdrug has had experience working in the pharmaceutical industry for the past 30 years.

Amexdrug Corporation, through its wholly-owned subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc., is a pharmaceutical and cosmeceutical company specializing in the research and development, manufacturing and distribution of pharmaceutical drugs, cosmetics and distribution of prescription and over-the-counter drugs, private manufacturing and labeling and a quality control laboratory. At Amexdrug Corporation, it is our anticipation to give our clientele the opportunity to purchase cost effective products while attempting to maximize the return of investments to our shareholders.

Amexdrug Corporation distributes its products through its subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc. primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities and other wholesalers and retailers in the state of California.

BioRx Pharmaceuticals, Inc. is a proud member of the National Association of Chain Drug Stores (NACDS).  BioRx Pharmaceuticals, Inc. has developed fourteen unique innovative products in the industry under the name Sponix.

Our team of professionals fully pledges the effectiveness of our distinct products.

At this time, we have certain distribution channels with suppliers and customers whom we know and trust, such as Amazon, and hundreds of independent pharmacies.  Of the estimated 100,000 retailers (drug stores and food mass), our goal is to have 20,000 stores carry our products in 2013.

References in this report to “we,” “our,” “us,” the “company” and “Amexdrug” refer to Amexdrug Corporation and also to our subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care.

Amexdrug currently has 1,000,000,000 shares of authorized common stock $.001 par value, of which 169,409,620 are issued and outstanding as of March 31, 2013, including  300,440 shares held as treasury shares.

Forward Stock Split and Increase in Authorized Shares

The Company’s Board of Directors approved a 20 to 1 forward stock split and an increase in the number of authorized shares of the Company’s common stock from 50,000,000 shares to 1,000,000,000 shares.  The par value remains at $0.001.  Both of these actions were approved pursuant to Section 78.209 of the Nevada Revised Statutes, and became effective on December 3, 2012.  After giving effect to the 20 to 1 forward stock split, the number of outstanding shares of the Company’s common stock increased from 8,470,481 pre-split shares to 169,409,620 post-split shares outstanding, as each outstanding share of the Company’s common stock became 20 shares as a result of the forward stock split.  The effects of the 20 to 1 forward stock split have been applied to the Company’s financial statements included in this report as though the forward stock split had already occurred.  The effects of the 20 to 1 forward stock split have also been applied to any share amounts and price per share amounts appearing in this report.

9

BioRx Pharmaceuticals

On November 8, 2004, Amexdrug formed a new subsidiary, BioRx Pharmaceuticals, Inc. as a Nevada corporation.  BioRx Pharmaceuticals, Inc. is committed to offer over the counter (OTC) products that are recommended with trust and faith by physicians, primarily podiatrists and dermatologists.  The focus and mission of BioRx Pharmaceuticals, Inc. is to create, develop and manufacture products to help ease pain and restore and maintain the overall well-being of our customers.  We strive for high performance and quality.  Our commitment is to offer natural and OTC products that are recommended with confidence by doctors and pharmacists and that the customer can use with pleasure.  Our compliance program is diligently followed through the Company. BioRx Pharmaceuticals, Inc. maintains high ethics for animal welfare and our products are never tested on animals.  All products are made in the USA.

A total of fourteen innovative health and wellness products have been manufactured for sale by BioRx Pharmaceuticals, Inc. These over-the-counter and natural products are effective for treatment of fungus, arthritis, sunburn protection and for healthy feet and nails.  BioRx Pharmaceuticals is planning to sell these products to national chain drugstores, sport chain stores, natural food markets and other mass markets. These products are being marketed under the name of Sponix, and are being sold under the name of BioRx Pharmaceuticals.

Allied Med, Inc.

On December 31, 2001, Amexdrug acquired all of the issued and outstanding common shares of Allied Med, Inc., an Oregon corporation, in a share exchange in a related party transaction.

Allied Med, Inc., was formed as an Oregon corporation in October 1997 to operate in the pharmaceutical wholesale business of selling a full line of brand name and generic pharmaceutical products, over-the-counter (OTC) drug and non-drug products and health and beauty products to independent and chain pharmacies, alternative care facilities and other wholesalers.  At Allied Med our sincere interest is our customers’ needs.  Our competitive discount pricing allows our customers an advantage.

Amexdrug assumed the operations of Allied Med, and Amexdrug has been building on the wholesale pharmaceutical operations of Allied Med.

The accompanying financial information includes the operations of Allied Med for all periods presented and the operations of Amexdrug Corporation from April 25, 2000.

Dermagen, Inc.

Amexdrug completed its purchase of Dermagen, Inc. on October 7, 2005.  Dermagen, Inc. is now an operating subsidiary of Amexdrug.  The acquisition of Dermagen, Inc. is not considered to be an acquisition of a significant amount of assets which would require audited financial statements of Dermagen, Inc.

Dermagen, Inc. is a growing manufacturing company specializing in the manufacturing and distribution of certain pharmaceuticals, medical devices, health and beauty products, and pharmacy and laboratory supplies.  Dermagen, Inc. has a U.S.-FDA registered and state FDA approved manufacturing facility licensed to develop high margin skin and novel health and beauty products for niche markets.  Dermagen’s competitive advantage is in its excellent product research and development.

Royal Health Care Company

In October 2003, Allied Med, Inc. acquired 100% of the assets of Royal Health Care Company.  Royal Health Care Company is a health and beauty company which has sold specially manufactured facial and body creams, arthritic pain relief medications and an exclusive patented hair care product to pharmacies, beauty salons, beauty supply stores and other fine shops. Royal Health Care Company uses the highest quality ingredients for the finest quality products. Each product has been formulated with the essential ingredients and plant extracts to achieve optimum potential and quality.  Royal Health Care Company products are manufactured by Dermagen, Inc. in an FDA approved manufacturing facility.

10

The Royal Health Care Company assets acquired include the “Royal Health Care Company” name, logo, and related trademarks, all formulas to products manufactured for sale under the Royal Health Care Company name, and the Royal Health Care Company list of customers.  These intellectual property rights were acquired without cost from a company in which Jack Amin’s wife is a principal shareholder.  Mr. Amin is the CEO and Chairman of Amexdrug Corporation and Allied Med, Inc.  Management believes this acquisition will provide the Company with an opportunity to increase the number of products sold by the Company, and expand the Company’s customer base.

On October 28, 2004, Amexdrug formed a new subsidiary, Royal Health Care, Inc. as a Nevada corporation.  Royal Health Care, Inc. was formed to manufacture and sell health and beauty products.

Lease Agreements and Certain Other Contracts

The Company's principal executive offices and its warehouse and distribution operations moved to 7251 Condor Street, Commerce California in March 2011.  The Company leases 27,500 square feet at this location..  The rental amount increased from $7,700 per month to $8,800 per month effective March 1, 2013.  Approximately 2,500 square feet of the premises is used for executive offices, and the balance of the premises is used for warehouse and distribution operations.  The lease is for a period of three years which commenced on March 1, 2011 and terminates on February 28, 2014.  The Company has the option to extend the lease for two additional three year periods.  If the Company exercises the first option to extend, the rental rate would increase to $9,900 per month effective March 1, 2014, $11,000 per month effective March 1, 2015 and $11,550 per month effective March 1, 2016. If the Company exercises the second option to extend, the rental rate would be adjusted to a fair market rental value as may be agreed to by the parties or as may be determined by an appraiser or arbitrator as provided in the Option to Extend Addendum. Payment of the lease has been personally guaranteed by Jack Amin and his wife, Nora Amin.  The Company believes this space will be sufficient for at least the next twelve months.

The Company’s Dermagen, Inc. manufacturing operations are currently located at 2500 East Fender Avenue, Units I&J, Fullerton, California, which is leased under one lease agreement dated March 1, 2011.  The Company leases approximately 3,520 square feet at a rental rate of $2,464 per month.  The lease was initially for a period of one year which commenced on March 1, 2011.  In early 2012, and again in early 2013, the parties executed Amendments to extend the lease term for one year.  The lease will now expire on February 28, 2014.  Payment of the lease has been personally guaranteed by Jack Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company believes that the various facilities covered by the leases described above will be sufficient for at least the next twelve months.

The Company’s loan agreement with Nora Amin is verbal.  The Company does not have written contracts with its major suppliers or buyers.  The Company has a written line of credit agreement with National Bank of California.  Copies of the Company’s written lease agreements and material contracts have been filed as exhibits to certain of its quarterly and annual reports.  See the Exhibit Index for a description of these agreements and for information on where copies can be found.

Business Segments

Since 2005, Amexdrug has had operations in two segments of its business, namely:  Distribution and Health and Beauty Products.  Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products.  Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.  Manufacturing includes expertise in research and development for health care industry products, including pharmacy supplies.

11

Results of Operations

Revenues

For the three months ended March 31, 2013, Amexdrug reported sales of $2,360,911, comprised of $1,718,431of sales from the Company’s pharmaceutical wholesale business of selling brand name and generic pharmaceutical products, and (OTC) health and beauty products, and $642,480 of sales of health and beauty products manufactured by the Company. This is $179,921 more than the $2,180,990of sales reported for the three months ended March 31, 2012 which was comprised primarily of $1,788,075 sales from the Company’s pharmaceutical wholesale distribution business of selling brand name and generic pharmaceutical products, and over the counter (OTC) health and beauty products, and $392,915 of sales of health and beauty products manufactured by the Company.  During the three month period ended March 31, 2013, Amexdrug experienced an increase in total sales due, in part, to increased marketing efforts.

Cost of Goods Sold

Cost of goods sold for the three months ended March 31, 2013 was $1,842,165, an increase of $21,815 from the $1,820,350 cost of goods sold for the three months ended March 31, 2012.

Gross Profit

During the three months ended March 31, 2013, gross profit increased by $158,106 to $518,746, or 22.0% of sales, from the $360,640, or  16.5% of sales, recorded for the three months ended March 31, 2012.  The change in gross profit margin is largely attributable to a larger percentage of sales of higher gross margin products sold in 2013.

Expenses

Total operating expenses for the three months ended March 31, 2013, consisting entirely of selling, general and administrative expenses were $243,208, an increase of $54,366 from the total operating expenses of $188,842 recorded for the three months ended March 31, 2012.  The increase in selling, general and administrative expense is primarily attributed to increased marketing expenses and increased compensation paid to the Company’s President in the later period.

Net Income

During the three months ended March 31, 2013, Amexdrug experienced net income of $172,345, an increase of $68,260 from the $104,085 of net income recorded for the three months ended March 31, 2012.  Amexdrug’s increase in net profits during the three month period ended March 31, 2013, is attributable largely to the larger gross profit generated from increased sales in the later period and to a larger percentage of sales of higher gross margin products sold in the later period.

Liquidity and Capital Resources – March 31, 2013

As of March 31, 2013, Amexdrug reported total current assets of $1,615,797, comprised primarily of cash and cash equivalents of $125,972, net accounts receivable of $640,419, and inventory of $832,633.  Total assets as of March 31, 2013 were $2,137,889, which included total current assets, plus net property and equipment of $473,859, other deposits of $29,862, trademark of $606, and goodwill of $17,765.

12

Amexdrug’s liabilities as of March 31, 2013, consisted primarily of accounts payable of $387,094, note payable to related party of $108,023, business lines of credit of $589,405, deferred tax liability of $55,500 and promissory note, current portion of $58,370.

During the three months ended March 31, 2013, Amexdrug used $158,980 cash in operating activities compared to $6,694  cash used in operating activities in the three months ended March 31, 2012.  The primary adjustments to reconcile net income to net cash used in operating activities during the first quarter of 2013 were as follows:  an increase in accounts receivable of $81,850, an increase in inventory of $31,697, a decrease in accounts payable and accrued liabilities of $310,744, and a decrease in prepaid expenses of $77,605.  Amexdrug had $125,972 in cash and cash equivalents at March 31, 2013. Operations have primarily been funded through net income and an increase in the credit line balances when needed.  Management does not anticipate that Amexdrug will need to seek additional financing during the next twelve months.

Stock Repurchases

Between approximately June 2007 and March 31, 2013, Amexdrug repurchased a total of 300,440 post-split shares of its common stock at prices ranging from a low of $0.01 per share to a high of $0.15 per share.  These shares are held by Amexdrug as treasury shares.  Amexdrug anticipates that it may make additional small purchases of its shares throughout the remainder of 2013.

Inflation

In the opinion of management, inflation has not and will not have a material effect on our operations in the immediate future. Management will continue to monitor inflation and evaluate the possible future effects of inflation on our business and operations.

Capital Expenditures

The Company expended $0 and $0 on capital expenditures during the three month periods ended March 31, 2013 and 2012, respectively.  The Company has no current plans for any significant capital expenditures.

Critical Accounting Policies

In the notes to the audited consolidated financial statements for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K, the Company discusses those accounting policies that are considered to be significant in determining the results of operations and its financial position. The Company believes that the accounting principles utilized by it conform to accounting principles generally accepted in the United States of America.

The preparation of financial statements requires Company management to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. By their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, the Company evaluates estimates. The Company bases its estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying value of assets and liabilities.  The actual results may differ from these estimates under different assumptions or conditions.

Forward-looking statements

This document includes various forward-looking statements with respect to future operations of Amexdrug that are subject to risks and uncertainties.  Forward-looking statements include information concerning expectations of future results of operations and such statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates” or similar expressions.  For those statements, Amexdrug claims the protection of the safe harbor for forward-looking statements contained in the Private Litigation Reform Act of 1995.  Actual results may vary materially.

13

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

A “smaller reporting company” (as defined by Item 10 of Regulation S-K) is not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Under the supervision and with the participation of management, our principal executive officer and principal financial officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”), as of March 31, 2013.  Based on this evaluation, our principal executive officer and our principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective and adequately designed to ensure that the information required to be disclosed by us in the reports we submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the applicable rules and forms and that such information was accumulated and communicated to our chief executive officer and chief financial officer, in a manner that allowed for timely decisions regarding required disclosures.

During the last fiscal quarter ended March 31, 2013, there has been no change in internal control over financial reporting that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

ANY FORWARD-LOOKING STATEMENTS INCLUDED IN THIS FORM 10-Q REPORT REFLECT MANAGEMENT’S BEST JUDGMENT BASED ON FACTORS CURRENTLY KNOWN AND INVOLVE RISKS AND UNCERTAINTIES.  ACTUAL RESULTS MAY VARY MATERIALLY.

PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.

Amexdrug’s subsidiary, Allied Med, Inc., is  presently a party to a legal proceeding.. On March 19, 2013,  Allied Med, Inc. (“Allied”) was named in a Complaint in the Court of Common Pleas in Hamilton County, Ohio (case no. A 1301927).  Nilpeter USA, Inc. (“plaintiff”) alleges that Allied Med, Inc. failed to fully pay for a mechanical press sold by Plaintiff to Allied.  Relief sought by Plaintiff is for $38,263.90, plus interest.  Allied Med, Inc. has a counter claim filed against the Plaintiff for misrepresentation about the performance of the piece of equipment purchased. Allied Med, Inc. has retained counsel to aggressively defend the matter.

To the best of Amexdrug’s knowledge, no governmental authority is contemplating the filing of any material legal proceeding against Amexdrug.

Item 1A.  Risk Factors.

A “smaller reporting company” (as defined by Item 10 of Regulation S-K) is not required to provide the information required by this Item.

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds.

During the three month period ended March 31, 2013, the Company did not issue any shares of its unregistered common stock.  For a description of any sales of shares of the Company’s unregistered stock made in the past three years, please refer to the Company’s Annual Reports on Form 10-K, and the Company’s Quarterly Reports on Form 10-Q filed since December 31, 2009.

Item 3.   Defaults Upon Senior Securities.

              None; not applicable.

Item 4.   Mine Safety Disclosures.

              None; not applicable.

Item 5.   Other Information.

  None; not applicable.

14

Item 6.   Exhibits.

          (a) Exhibits.

The following exhibits are filed as part of this report.

Exhibit	Exhibit
Number	Description	Location
2.1	Agreement and Plan of Merger (to change domicile from California)	1
2.2	Agreement and Plan of Reorganization	2
3.1	Articles of Incorporation	3
3.2	By-Laws	3
3.3	Certificate of Change Pursuant to N.R.S. Sec. 78.209	9
10.1	Promissory Note with National Bank of California dated June 23, 2008	5
10.2	Change in Terms Agreement with National Bank of California dated June 9, 2009	5
10.3	Change in Terms Agreement with National Bank of California dated March 3, 2009	6
10.4	Change in Terms Agreement with National Bank of California dated December 21, 2011	8
10.5	Change in Terms Agreement with National Bank of California dated June 9, 2012	9
10.6	Subordination Agreement between Nora Y. Amin, National Bank of California, Amexdrug and its subsidiaries dated June 9, 2009	6
10.7	Business Loan Agreement between National Bank of California, Amexdrug and its subsidiaries dated June 23, 2008	6
10.8	Commercial Security Agreement between National Bank of California, Amexdrug and its subsidiaries dated June 23, 2008	6

15

10.9	Commercial Guarantee between National Bank of California, Jack N. Amin, Amexdrug and its Subsidiaries	6
10.10	Commercial Guarantee between National Bank of California, Nora Y. Amin, Amexdrug and its subsidiaries	6
10.11	Lease Agreement between Fullerton Business Center, LLC, Lessor, and Allied Med, Inc Lessee, dated March 1, 2011 (Units I & J)	7
10.12	First Amendment to Lease Extending Lease Term(Units I & J) dated January 18, 2012	8
10.13	Fifth Amendment to Lease Extending Lease Term(Units I & J) dated February 20, 2013	10
10.14	Guaranty of Lease by Jack Amin (Units I & J)
10.15	Lease Agreement between Condor Associates, LLC, Lessor, and Allied Med, Inc., Lessee, dated February 22, 2011
10.16	Business Loan Agreement between National Bank of California, Amexdrug and its Subsidiaries dated July 30, 2012	9
10.17	Promissory Note with National Bank of California Dated July 30, 2012	9
14.1	Code of Ethics	4
21.1	List of Subsidiaries of Amexdrug Corporation	6
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002	This Filing
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes- Oxley Act of 2002	This Filing
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes- Oxley Act of 2002	This Filing
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes- Oxley Act of 2002	This Filing

16

101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase
	Summaries of all exhibits contained within this report are modified in their entirety by reference to these Exhibits.
1	Exhibit 2.1 is incorporated by reference from Amexdrug’s Form 8-K Current Report filed December 21, 2001 as Exhibit No. 10.01.
2	Exhibit 2.2 is incorporated by reference from Amexdrug’s Form 8-K Current Report filed January 15, 2002 as Exhibit No. 10.01.
3	Exhibit 3.1 and 3.2 are incorporated by reference from Amexdrug’s Form 10-KSB for the years ended December 31, 2001 filed on April 1, 2002.
4	Exhibit 14.1 is incorporated by reference from Amexdrug’s Form 10-K for the year ended December 31, 2008 filed April 13, 2009
5	Exhibits 10.1 and 10.2 are incorporated by reference From Amexdrug’s Form 10-Q for the period ended June 30, 2009 filed August 14, 2009
6	Exhibits 10.3, 10.6 through 10.10 and 21.1 are incorporated by reference from Amexdrug’s Form 10-Q/A for the period ended June 30, 2009 filed September 18, 2009
7	Exhibits 10.11 and 10.14 through 10.16 are incorporated by reference from Amexdrug’s Form 10-K for the year ended December 31, 2010 filed March 31, 2011
8	Exhibits 10.4 and 10.12 are incorporated by reference from Amexdrug’s Form 10-K for the year ended December 31, 2011 filed March 31, 2012
9	Exhibits 3.3, 10.5, 10.16 and 10.17 are incorporated by reference from Amexdrug’s Form 10-Q for the period ended September 30, 2012 filed November 14, 2012
10	Exhibit 10.13 is incorporated  by reference from Amexdrug’s Form 10-K for the year ended December 31, 2012 filed April 3, 2013
11	Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed “furnished” and not “filed” or part of a registration statement or prospectus for purposes of Sections 11 and 12 of  the Securities Act of 1933, or deemed “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under these sections.

17

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMEXDRUG CORPORATION
Date: May 20, 2013	By:/s/ Jack Amin
	Jack Amin
	Director, President, Chief Executive
	Officer, Chief Financial Officer and
	Chief Accounting Officer

17

EX-31.1

EXHIBIT 31.1

SECTION 302

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Jack Amin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amexdrug Corporation,

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2013	By: /s/ Jack Amin
	Jack Amin, Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SECTION 302

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Jack Amin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amexdrug Corporation,

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2013	By: /s/ Jack Amin
	Jack Amin, Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Amexdrug Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jack Amin, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jack Amin

Jack Amin

Chief Executive Officer

May 20, 2013

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company's Form 10-Q solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and are not being filed as part of the Form 10-Q or as a separate disclosure document.

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Amexdrug Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jack Amin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jack Amin

Jack Amin

Chief Financial Officer

May 20, 2013

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company's Form 10-Q solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and are not being filed as part of the Form 10-Q or as a separate disclosure document.

XML

4. Income Taxes

3 Months Ended

Mar. 31, 2013

Notes

4. Income Taxes

4.     INCOME TAXES

The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2009.

        The Company accounts for uncertainty in tax positions by recognition in the financial statements. 

        The Company's policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

XML

3. Capital Stock

3 Months Ended

Mar. 31, 2013

Notes

3. Capital Stock

3.     CAPITAL STOCK

During the three months ended March 31, 2013, the Company issued no shares of common stock.

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 125,972	$ 415,962
Investment	5,348	5,991
Accounts receivable, net of allowance of $7,833 and $7,833, respectively	640,419	558,569
Prepaid expenses		77,605
Inventory	832,633	800,936
Other asset	11,425	11,002
Total Current Assets	1,615,797	1,870,065
Property and Equipment, at cost
Office and computer equipment	700,736	698,339
Leasehold improvements	15,700	15,700
Property and Equipment, gross	716,436	714,039
Less accumulated depreciation	(242,577)	(224,935)
Net Property and Equipment	473,859	489,104
Other Assets
Other deposits	29,862	29,862
Customer base, net of accumulated amortization of $18,259
Trademark, net of accumulated amortization of $42 and $1,002, respectively	606	648
Goodwill	17,765	17,765
Total Other Assets	48,233	48,275
Total Assets	2,137,889	2,407,444
Current Liabilities:
Accounts payable	387,094	697,339
Accrued liabilities	8,284	8,780
Deferred operating lease liability	13,192	14,590
Deferred tax liability	55,500	57,300
Corporate tax payable	1,915
Notes payable related parties	108,023	108,023
Business lines and short term promissory note	589,405	697,842
Promissory note, current portion	58,370	58,370
Total Current Liabilities	1,221,783	1,642,244
Long Term Liabilities
Promissory note	315,347	335,550
Total Long Term Liabilities	315,347	335,550
Total Liabilities	1,537,130	1,977,794
Shareholders' Equity
Common stock, $0.001 par value; 1,000,000,000 authorized common shares 169,409,620 shares issued and outstanding	169,410	169,410
Additional paid in capital	(77,594)	(77,594)
Treasury stock	(16,169)	(14,933)
Retained earnings	525,112	352,767
Total Shareholders' Equity	600,759	429,650
Total Liabilities and Shareholders' Equity	$ 2,137,889	$ 2,407,444

XML

1. Basis of Presentation

3 Months Ended

Mar. 31, 2013

Notes

1. Basis of Presentation

1.     BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.  For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2012.

XML

2. Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2013

Notes

2. Summary of Significant Accounting Policies

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of AmexDrug Corporation is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

        Income per Share Calculations

Income per Share dictates the calculation of basic earnings per share and diluted earnings per share. Basic earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted income per share is the same as the basic income per share for the three months ended March 31, 2013, because there are no outstanding dilutive instruments.

XML

CONSOLIDATED BALANCE SHEETS PARENTHETICAL (USD $)	Mar. 31, 2013	Dec. 31, 2012
CONSOLIDATED BALANCE SHEETS PARENTHETICAL
Allowance for doubtful accounts receivable	$ 7,833	$ 7,833
Amortization of customer relationships	18,259	18,259
Accumulated amortization - trademarks	$ 42	$ 1,002
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	1,000,000,000	1,000,000,000
Common stock shares issued	169,409,620	169,409,620
Common stock shares outstanding	169,409,620	169,409,620

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	May 14, 2013
Document and Entity Information
Entity Registrant Name	AMEXDRUG CORP
Document Type	10-Q
Document Period End Date	Mar. 31, 2013
Amendment Flag	false
Entity Central Index Key	0000045621
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		169,409,620
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1

XML

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues
Sales	$ 2,360,911	$ 2,180,990
Cost of Goods Sold	1,842,165	1,820,350
Gross Profit	518,746	360,640
Operating Expenses
Selling, general and administrative expense	243,208	188,842
Total Operating Expenses	243,208	188,842
Income before depreciation expense	275,538	171,798
Depreciation and amortization expense	17,683	2,472
Income before Other Income/(Expenses)	257,855	169,326
Other Income/(Expenses)
Interest and other income	1	2
Unrealized gain/(loss)	618	1,415
Interest expense	(8,409)	(5,372)
Total Other Income/(Expenses)	(7,790)	(3,955)
Income before Provision for Income Taxes	250,065	165,371
Income tax expense	(77,720)	(61,286)
Net Income	$ 172,345	$ 104,085
BASIC AND DILUTED INCOME PER SHARE	$ 0.00	$ 0.00
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	169,409,620	169,409,620

XML

7. Commitments and Contingencies

3 Months Ended

Mar. 31, 2013

Notes

7. Commitments and Contingencies

7.     COMMITMENTS AND CONTINGENCIES

        Operating Leases                                                                                                                                     

The Company moved to a new facility and signed a new operating lease for three years as of March 1, 2011. The monthly lease payments per month are $7,600. There are future minimum rental payments required under the operating leases for the facility.  The lease of the facility expires in 2014. 

Legal Contingency

On March 19, 2013, the Company received notice of a claim filed by a vendor requesting an additional payment of $38,264 for a piece of equipment that was purchased by the Company. The Company has a counter claim filed against the vendor for misrepresentation about the performance of the piece of equipment purchased. The Company has retained counsel to aggressively defend the matter.

XML

6. Subsequent Event

3 Months Ended

Mar. 31, 2013

Notes

6. Subsequent Event

6.     SUBSEQUENT EVENT

        Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has determined there are no subsequent events to be reported.

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 172,345	$ 104,085
Adjustment to reconcile net income to net cash used in operating activities
Depreciation and amortization	17,683	2,472
Unrealized (gain)/loss on investment	(618)	(1,415)
Allowance for doubtful accounts
Adjustment to retained earnings
(Increase) Decrease in:
(Increase) Decrease in accounts receivable	(81,850)	110,934
(Increase) Decrease in inventory	(31,697)	(215,612)
(Increase) Decrease in prepaid expenses	77,605	45,513
(Increase) Decrease in deferred tax asset		8,009
(Increase) Decrease in other assets	(422)	(45,513)
Increase (Decrease) in:
Increase (Decrease ) in accounts payable and accrued liabilities	(310,744)	(69,796)
Increase (Decrease ) in deferred operating lease liability	(1,397)	1,352
Increase (Decrease ) in deferred tax liability	(1,800)
Increase (Decrease ) in corporate income tax payable	1,915	53,277
NET CASH USED IN OPERATING ACTIVITIES	(158,980)	(6,694)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments	1,261
Proceeds from the sale of investment		(2,028)
Purchase of fixed assets	(2,397)
NET CASH USED BY INVESTING ACTIVITIES	(1,136)	(2,028)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on related party loans		(1,671)
Purchase of treasury stock	(1,235)	(947)
Proceeds from promissory note
Payments on promissory note	(20,202)
Proceeds from credit line	(108,437)	(450,425)
NET CASH USED BY FINANCING ACTIVITIES	(129,874)	(453,043)
NET DECREASE IN CASH	(289,990)	(461,765)
CASH, BEGINNING OF PERIOD	415,962	589,472
CASH, END OF PERIOD	125,972	127,707
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	6,253	3,212
Income taxes

XML

5. Business Segment Information

3 Months Ended

Mar. 31, 2013

Notes

5. Business Segment Information

5.     BUSINESS SEGMENT INFORMATION

Beginning in 2005, the Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

        The following tables describe information regarding the operations and assets of these reportable business segments:

		Health and
		Beauty
	Distributions	Products	Total
For the period ended March 31, 2013
Sales to external customers	$1,718,431	$642,480	$2,360,911
Depreciation and amortization	1,309	16,374	17,683
Segment income (loss) before taxes	15,637	156,708	172,345
Segment assets	631,667	1,506,222	2,137,889
For the period ended March 31, 2012
Sales to external customers	$1,788,075	$392,915	$2,180,990
Depreciation and amortization	933	1,539	2,472
Segment income (loss) before taxes	64,258	101,113	165,371
Segment assets	679,594	554,783	1,234,377